|
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). |
|
|
Honoraria - AstraZeneca; Celgene; Clovis Oncology; Eisai; Genomic Health; MSD; Pfizer; Roche; Tesaro |
Consulting or Advisory Role - Amgen; AstraZeneca; CureVac; Eisai; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Pfizer; PharmaMar; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Roche; Tesaro |
Research Funding - PharmaMar (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro |
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; MSD; Novartis; PharmaMar; Roche; Tesaro |
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Novartis; Pfizer; PharmaMar; Roche |
Research Funding - AstraZeneca (Inst); Roche |
|
|
Honoraria - Roche Pharma AG; Tesaro |
Consulting or Advisory Role - Tesaro |
Travel, Accommodations, Expenses - Tesaro |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Roche; Tesaro |
Travel, Accommodations, Expenses - Roche; Tesaro |
|
|
|
Consulting or Advisory Role - Roche |
|
|
Consulting or Advisory Role - AstraZeneca; PharmaMar; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Tesaro |
|
|
Honoraria - AstraZeneca; Lilly; PharmaMar; Roche; Stryker; Tesaro; Zai Lab |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Immunogen; Lilly; PharmaMar; Roche; Tesaro |